Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.
Ginkgo Bioworks has received investment from 2 venture capital firms.
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly.
Ginkgo Bioworks has received investment from FundersClub, Starting Line. These venture capital firms and investors provide both capital and strategic support.
Ginkgo Bioworks has raised $290M in total funding. The company operates in the Biotech sector.
Ginkgo Bioworks was founded in 2008.
Ginkgo Bioworks operates in the Biotech sector. Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly.
